Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,245.34 +1,316.75 (+2.27%) CMC Crypto 200
1,278.91 +8.17 (+0.64%)
PROCEPT BioRobotics Corporation (PRCT)
After hours:
| Previous close | 60.61 |
| Open | 62.63 |
| Bid | 61.68 x 100 |
| Ask | 61.83 x 200 |
| Day's range | 59.27 - 62.90 |
| 52-week range | 24.83 - 63.26 |
| Volume | |
| Avg. volume | 537,575 |
| Market cap | 3.173B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 mi
- GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Japanese post market survey supports safety and efficacy of Aquablation therapySAN JOSE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the presentation of a late breaking post-market survey at the Japanese Urological Association (JUA) Annual Meeting on positive Aquablation therapy outcomes for men in Japan w
- GlobeNewswire
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trialsSAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign
